Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 50 EV-to-EBIT is 55.71 as of Jul. 22, 2026, which is 3139% above its 10-year median of 1.72. GuruFocus rates LSE:SPEC with a GF Score™ of 50/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Inspecs Group ranks worse than 87.96% on this metric.
The historical rank and industry rank for Inspecs Group's EV-to-EBIT or its related term are showing as below:
LSE:SPEC'
s EV-to-EBIT Range Over the Past 10 Years
Min: -93.11 Med: 1.72 Max: 55.71
Current: 55.71
During the past 10 years, the highest EV-to-EBIT of Inspecs Group was 55.71. The lowest was -93.11. And the median was 1.72.
LSE:SPEC's EV-to-EBIT is ranked worse than 87.96% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.28
vs LSE:SPEC: 55.71
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Inspecs Group's Enterprise Value for the quarter that ended in Dec. 2025 was £116.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inspecs Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £2.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group EV-to-EBIT Related Terms
Inspecs Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Inspecs Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SPEC vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Inspecs Group's EV-to-EBIT falls into.
Inspecs Group's current Enterprise Value is £149.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inspecs Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £2.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (LSE:SPEC) has a EV-to-EBIT of 55.71 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Inspecs Group and its competitors. This is 3139% above median its historical median of 1.72. According to the industry distribution chart, Inspecs Group ranks #409 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 88%.
Is Inspecs Group's EV-to-EBIT too high?
Inspecs Group's current EV-to-EBIT of 55.71 is 3139% above median its 10-year median of 1.72. The Medical Devices & Instruments industry median EV-to-EBIT is 18.28. Inspecs Group's value of 55.71 is 204.8% above this industry median. Based on the distribution chart, Inspecs Group ranks #409 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Inspecs Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #409 out of 465 companies for EV-to-EBIT. This places Inspecs Group in the lower half of its industry. The industry median EV-to-EBIT is 18.28. Inspecs Group's value of 55.71 is 204.8% above this benchmark. While the company's 10-year median is 1.72 vs. the industry median of 18.28, Inspecs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.28, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current EV-to-EBIT of 55.71 is 204.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current EV-to-EBIT is 55.71, which is 3139% above median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.97 — trading 67.2% above its estimated fair value. The current EV-to-EBIT is 55.71, which is 3139% above median its 10-year median of 1.72 and 204.8% above the Medical Devices & Instruments industry median of 18.28. Inspecs Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current EV-to-EBIT is 55.71 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.97 is trading 67.2% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
EV-to-EBIT: 55.71 (3139% above median its 10-year median of 1.72)
GF Value™: £0.58 vs. price of £0.97 (67.2% above fair value)
Industry Position: 204.8% above the Medical Devices & Instruments median (#409 of 465)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
50GF Score
Get the complete analysis for LSE:SPEC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
